Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Vaccines
•
Allergy & Immunology
Why are influenza and COVID vaccines still recommended for patients on immunoglobulin replacement therapy?
Related Questions
Does splitting the dose of a vaccine during an observed administration affect the efficacy of the vaccine response?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Do patients with a PEG allergy have a contraindication to receiving mRNA vaccines?
Do you consider immunoglobulin replacement in a patient who has rapidly waning vaccine titers but does appropriately respond to revaccination?
Do mRNA vaccines lead to increased rates of acute/chronic urticaria?
How long do you counsel patients to wait after rituximab therapy before getting live vaccines?
Are there concerns with combining anti-IL5 biologics (mepolizumab or benralizumab) for severe asthma with other biologics for RA (e.g. TNFi)?
Do you utilize any desensitization protocols for delayed hypersensitivity reactions?
Is there any non-invasive validated testing for Annatto (E-160b), also known as norbixin?
What functional assays do you recommend to determine if MGRPRX2 receptor activation has led to a non-IgE mediated anaphylaxis?
